Abstract: The invention relates to medicine.A composition for treatment of progressive myopia is composed of the following constituents, taken in mass percent:______________________________________ a mixture of polyvinylpyrrolidone, acrylamide- 18.8 to 29.5 hydrazide, and ethylacrylate (1;1;1) an aqueous solution, containing the follow- 69.5 to 80.1 ing ingredients, taken in mg/l: hydrochloric acid 940.0 boric acid 4.12 ferrous oxide 115.0 cupric citrate 16.0 3-percent aqueous hydrogen peroxide 0.79 to 0.89 dichlorodi-[ 2-methyl-3-hydroxy-4,5-di- 0.11 to 0.31.

Abstract: An antianginal composition in the form of a plate is provided for treating ischemic heart disease and is comprised of a biologically soluble and resolvable film and an antianginal coronary vasodilating nitrate. This film is placed buccally on the gum or mouth mucosa for rapid arresting or prevention of angina pectoris attacks.The antianginal film is in the form of a plate, 0.1 to 1.5 mm thick, consisting of a biologically soluble and resolvable carrier. Preferably, the film is comprised of a homoploymer of acrylamide or vinylpyrrolidone, or a copolymer thereof with acrylate, containing from 99 to 70 percent by weight of acrylamide with vinylpyrrolidone and from 1 to 30 percent by weight of acrylate having a molecular mass from 50,000 to 1,000,000, and the active principle having antianginal action, the components being taken in the following proportions, in percent by weight:______________________________________ active substance having 3.0-30.0 antianginal action biologically soluble and 70.0-97.

Abstract: An antianginal composition in the form of a plate is provided for treating ischemic heart disease and is comprised of a biologically soluble and resolvable film and an antianginal coronary vasodilating nitrate. This film is placed buccally on the gum or mouth mucosa for rapid arresting or prevention of angina pectoris attacks.The antianginal film is in the form of a plate, 0.1 to 1.5 mm thick, consisting of a biologically soluble and resolvable carrier. Preferably, the film is comprised of a homopolymer of acrylamide or vinylpyrrolidone, or a copolymer thereof with acrylate, containing from 99 to 70 percent by weight of acrylamide with vinylpyrrolidone and from 1 to 30 percent by weight of acrylate having a molecular mass from 50,000 to 1,000,000 and the active principle having antianginal action, the components being taken in the following proportions, in percent by weight:active substance having antianginal action: 3.0-30.0biologically soluble and resolvable carrier: 70.0-97.

Abstract: The antianginal film is a plate, 0.1 to 1.5 thick, consisting of a biologically soluble and resolvable carrier, which is a hompolymer of acrylamide or vinylpyrrolidone, or a copolymer thereof with acrylate, containing from 99 to 70 percent by weight of acrylamide with vinylpyrrolidone and from 1 to 30 percent by weight of acrylate having a molecular mass from 50,000 to 1,000,000, and the active principle having antianginal action, the components being taken in the following proportions, in percent by weight:active substance having antianginal action 3.0-30.0biologically soluble and resolvable carrier 70.0-97.

Abstract: A pharmaceutical preparation for the treatment of diabetes mellitus comprising the following components, in percent by weight:______________________________________ crystalline insulin with a conventional 1 to 25.0 activity of 1 mg = 20 units additives inhibiting deactivation of insulin, 0.02 to 10.0 viz. 5-(para-[N--(3-methoxypyridazinyl-6)- sulphamido]-phenylazo)-salicylic acid, calcium gluconate or a mixture thereof preservatives 0.1 to 15.0 additives adjusting solubility of 0.01 to 10.0 insulin water-soluble polymeric base the balance.

Abstract: This invention relates to medical technique and more particularly it relates to biodestructive materials used to manufacture elements for fixation of bone fragments.Said material contains a matrix of non-toxic polymer resolvable in the body consisting of hydrophilic and hydrophobic repeat units, and a reinforcing component of non-toxic fibres or threads resolvable in the body. The matrix polymer is preferably a copolymer of methyl methacrylate and N-vinyl pyrrolidone, and the reinforcing component is preferably fibre or threads of polyamide and oxycellulose.Said material can be used in medicine for fixation of bone fragments in fractures or injuries of bones.